XCancer

A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II Trial to Compare Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab) Versus Selective Internal Radiation Therapy (SIRT-Y90) Followed by Placebo in Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

Description:

This is a multi-national, phase II, parallel-arm, double-blind, placebo-controlled, two-arm study designed to assess the efficacy and safety of SIRT-Y90 followed by atezolizumab plus bevacizumab [study arm], versus SIRT-Y90 followed by placebo [control arm] in patients with locally advanced Hepatocellular Carcinoma (HCC).

Sponsor:

National Cancer Centre, Singapore

Phase:

Phase 2

Contacts:

Professor Pierce CHOW, MD, PhD (Principal Investigator)

pierce.chow.k.h@singhealth.com.sg

+65 6436 8000

Qingguang HAN

han.qingguang@nccs.com.sg

+65 6576 7657

Government Study Link:

NCT05377034 - Click here to see study on

ClinicalTrials.gov